Loading organizations...
Loading organizations...
Biopharmaceutical company developing drugs for undruggable protein targets.
Parabilis Medicines has raised $305.0M across 1 funding round.
Parabilis Medicines has raised $305.0M in total across 1 funding round.
Parabilis Medicines has raised $305.0M in total across 1 funding round.
Parabilis Medicines's investors include Jake Simson, Catalio Capital Management, Foresite Capital, ARCH Venture Partners, Cormorant Asset Management, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Invus, Marshall Wace.
Parabilis Medicines has raised $305.0M across 1 funding round. Most recently, it raised $305.0M Series F in January 2026.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 8, 2026 | $305.0M Series F | Jake Simson | Catalio Capital Management, Foresite Capital, ARCH Venture Partners, Cormorant Asset Management, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Invus, Marshall Wace, Milky Way Investments, Nextech Invest, Rock Springs Capital, Sixty Degree Capital, Soleus Capital, T. Rowe Price Associates |